| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b758fecaba243429625442aa212e8701 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-24 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-26 |
| filingDate |
2015-04-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_43ba09dcae023d7ffcde716d46833856
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ba45415d76329c3e348fe660de4e5c2 |
| publicationDate |
2017-02-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017044107-A1 |
| titleOfInvention |
Inhibitors of JMJD2C as Anticancer Agents |
| abstract |
The present disclosure provides compounds, pharmaceutical compositions and related methods for the treatment of cancer, e.g., castration-resistant prostate cancer (CRPC). Specifically, the present disclosure provides a series of 8-hydroxyquinoline derivatives which show cytotoxic effects on androgen-independent prostate cancer cells. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2019100769-A1 |
| priorityDate |
2014-04-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |